In an important new perspective, Dr. Sheng-Cai Lin of Xiamen University unifies three distinct longevity interventions—caloric restriction (CR), Metformin, and bile acids—into a single, convergent molecular pathway. The central discovery is that glucose itself is a signaling molecule, not just a fuel. Lin’s team has mapped a precise “lysosomal glucose-sensing pathway” that acts as the master switch for aging.
The narrative overturns the textbook view that AMPK (the cell’s energy sensor) is activated solely by low ATP (energy deficit). Instead, Lin reveals that Aldolase, a glycolytic enzyme, physically senses the absence of glucose-derived metabolites (specifically Fructose-1,6-bisphosphate or FBP). When FBP drops, Aldolase triggers a domino effect on the lysosome surface, inhibiting the proton pump (v-ATPase) and recruiting the “AXIN” protein scaffold to activate AMPK.
Crucially, this paper demonstrates that Metformin (via the PEN2 protein) and Lithocholic Acid (a bile acid elevated during fasting, via TULP3) hijack this exact same lysosomal machinery to trigger longevity signals. The team believes they have effectively cracked the code of how fasting works and translated it into a novel drug candidate, Aldometanib, which mimics glucose starvation without actual starvation, extending lifespan and mobilizing immune cells to fight cancer.
Source
-
Open Access Paper: Pioneers: Glucose Sensing and Control of Health-span and Lifespan
-
Institution: School of Life Sciences, Xiamen University, Fujian, China.
-
Journal: Journal of Molecular Biology.
-
Impact Evaluation The impact score of this journal is ~4.7 (Impact Factor) / 10.2 (CiteScore). Therefore, this is a Medium-High impact journal.
Part 2: The Biohacker Analysis
Study Design Specifications
-
Type: Perspective & Review of Primary Research. (Note: This document summarizes a body of work spanning ~2013–2025, rather than presenting a single new dataset).
-
Subjects (in referenced key experiments):
-
Mice: C57BL/6J (referenced in underlying studies for Aldometanib and Metformin work).
-
C. elegans: Used for initial lifespan screening of Metformin and Aldometanib.
-
Cell Lines: HEK293T, MEFs (Mouse Embryonic Fibroblasts), and Hepatocellular Carcinoma (HCC) models.
Lifespan Analysis
-
Control Group Audit: The specific survival curves required to audit the control group against the Harrison et al. benchmark (expected median ~800-900 days for C57BL/6J) are not present in this summary text. The author cites their 2022 Nature Metabolism paper for the raw data.
-
Warning: Without the raw Kaplan-Meier curves, we cannot confirm if the “extension” was due to robust drug effects or short-lived controls.
-
Claimed Extension:
-
Aldometanib (Synthetic Aldolase Inhibitor): Reported ~7.5% extension in murine lifespan.
-
Metformin: Cited as extending lifespan in C. elegans and mice via the PEN2-lysosomal pathway, though specific % stats for mice are generalized in this text.
-
Lithocholic Acid (LCA): Described as a “CR mimetic” that phenocopies anti-aging effects of calorie restriction.
2 Likes
Based on the current scientific literature, Aldometanib (also known as LXY-05-029) is in the Preclinical stage of development.
It is currently a research-grade chemical compound used in in vitro (cell culture) and in vivo (animal) studies. There is no evidence of active human clinical trials (Phase I, II, or III) or FDA approval for human use.
Development Status Summary
| Category |
Status |
| Current Stage |
Preclinical / Basic Research |
| Primary Identifier |
LXY-05-029 |
| Target Mechanism |
Selective inhibitor of Aldolase A (ALDOA); activates lysosomal AMPK
|
| Human Trials |
None (Not yet tested in humans) |
| Commercial Status |
Available for Research Use Only (e.g., Selleck, MedChemExpress) |
1 Like
The Liver-Eye Axis: How Your Metabolism Dictates Your Vision
For decades, bile acids (BAs) were dismissed as mere biological detergents, essential only for emulsifying fats in the gut. However, a landmark review published in iScience reveals a far more complex reality: the liver and the eye are locked in a sophisticated molecular dialogue known as the “hepato-ocular axis”. This research positions bile acids as pleiotropic signaling molecules that act as a bridge between hepatic metabolic health and ocular integrity.
When the liver’s metabolic machinery falters—whether through genetic defects or acquired conditions like Nonalcoholic Fatty Liver Disease (NAFLD) —the resulting “spillover” of dysregulated bile acids can devastate vision. The paper details how aberrations in BA synthesis and transport lead to systemic accumulation of toxic intermediates. These compounds cross the blood-retinal barrier (BRB) , triggering direct cytotoxicity, oxidative stress, and the disruption of retinal and lens homeostasis. Clinical data already show a strong correlation between fatty liver and elevated intraocular pressure (IOP) , as well as associations between primary biliary cholangitis and dry eye syndrome.
The review highlights FXR and TGR5 as the primary receptor “hubs” that translate bile acid fluctuations into cellular action. While toxic concentrations drive damage, specific bile acid derivatives like TUDCA and UDCA exhibit profound neuroprotective effects. These compounds act as chemical chaperones, stabilizing proteins, alleviating Endoplasmic Reticulum (ER) stress , and suppressing inflammatory cascades like the NLRP3 inflammasome.
Ultimately, the researchers propose a shift in how we treat chronic eye diseases. Instead of viewing retinal degeneration or cataracts as isolated ocular events, they should be treated as systemic metabolic failures. By reconstructing systemic bile acid homeostasis through targeted supplementation, microbiome modulation, or nanotechnology, clinicians may soon be able to treat the eye by fixing the liver.
Actionable Insights
-
Monitor the Liver-Eye Connection: Patients with NAFLD or elevated liver enzymes should undergo rigorous ophthalmological screening for early signs of glaucoma (elevated IOP) and retinopathy, as these conditions share a molecular basis.
-
Target the Microbiome: Diversifying gut microbiota is critical; a reduction in Megamonas species is linked to both POAG and NAFLD, suggesting that microbiome-driven bile acid balance is essential for ocular health.
-
Explore Endogenous Cytoprotectants: Compounds like TUDCA and UDCA (already FDA-approved for specific liver conditions) show promise in protecting Retinal Ganglion Cells (RGCs) and stabilizing the blood-retinal barrier.
-
Nutritional Support for Transport: Since bile acid transport defects impair the absorption of fat-soluble vitamins (A, E, K) and DHA, ensuring adequate levels of these nutrients is vital for preventing night blindness and retinal oxidative damage.
-
Emerging Therapeutics: Look toward future FXR agonists and ASBT inhibitors , which aim to recalibrate the bile acid pool to favor hydrophilic, protective species over toxic, hydrophobic ones.
Source:
-
Open Access Paper: Hepato-ocular crosstalk: Bile acids bridging pathogenesis and therapy
-
Institution: Key Laboratory for Quality Evaluation of Bulk Herbs of Hunan Province, School of Pharmacy, Hunan University of Chinese Medicine.
-
Country: China.
-
Journal Name: iScience (Cell Press).
-
Impact Evaluation: The impact score (CiteScore/JIF) of this journal is approximately 5.8–6.1, evaluated against a typical high-end range of 0–60+ for top general science journals; therefore, this is a Medium-to-High impact journal.